Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act

Ann Intern Med. 2019 Oct 15;171(8):578-579. doi: 10.7326/M19-1218. Epub 2019 Oct 1.

Authors

Theodore T Lee¹, Daniel H Solomon², Aaron S Kesselheim³

Affiliations

¹ Yale Law School, Yale University, New Haven, Connecticut (T.T.L.).
² Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (D.H.S.).
³ Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.S.K.).

PMID: 31569216
DOI: 10.7326/M19-1218

No abstract available

MeSH terms

Arthritis / etiology
Cardiovascular Diseases / chemically induced
Chronic Pain / drug therapy
Hemophilia A / complications
Humans
Lactones / adverse effects
Lactones / therapeutic use*
Orphan Drug Production / legislation & jurisprudence*
Sulfones / adverse effects
Sulfones / therapeutic use*
United States

Substances

Lactones
Sulfones
rofecoxib